Food Extracts Consumed in Mediterranean Countries and East Asia Reduce Protein Concentrations of Androgen Receptor, Phospho-Protein Kinase B, and Phospho-Cytosolic Phospholipase A2{alpha} in Human Prostate Cancer Cells  

Oleh:

Singh, Jaskirat ; Chanlu, Xie ; Mu, Yao ; Sheng, Hua ; Vignarajan, Soma

Jenis: Article from Journal - ilmiah internasional
Dalam koleksi: JN: The Journal of Nutrition vol. 140 no. 04 (Apr. 2010), page 786.

Ketersediaan

Perpustakaan FK Nomor Panggil: J42.K.2010.01 Non-tandon: 1 (dapat dipinjam: 0) Tandon: tidak ada

Lihat Detail Induk

Isi artikel

Active surveillance is an emerging management option for the rising number of men with low-grade, clinically localized prostate cancer. However, 30–40% of men on active surveillance will progress to high-grade disease over 5 y. With the ultimate aim of developing a food-based chemoprevention strategy to retard cancer progression in these otherwise healthy men, we have developed a blend of food extracts commonly consumed in Mediterranean countries and East Asia. The effect of the food extracts known as Blueberry Punch (BBP) on prostate cancer cell growth and key signaling pathways were examined in vitro and in vivo. BBP reduced prostate cancer cell growth in a dose-dependent manner (0.08–2.5%) at 72 h in vitro due to the reduction in cell proliferation and viability. Prostate cancer cell xenograft-bearing mice, administered 10% BBP in drinking water for 2 wk, had a 25% reduction in tumor volume compared with the control (water only). In vitro, BBP reduced protein concentrations in 3 signaling pathways necessary for the proliferation and survival of prostate cancer cells, namely androgen receptor, phospho-protein kinase B/protein kinase B, and phospho-cytosolic phospholipase A2{alpha}. The downstream effectors of these pathways, including prostate-specific antigen and glycogen synthase kinase 3ß, were also reduced. Thus, this palatable food supplement is a potential candidate for testing in clinical trials and may ultimately prove effective in retarding the progression of low-grade, early-stage prostate cancer in men managed by active surveillance.

Opini Anda

Klik untuk menuliskan opini Anda tentang koleksi ini!

Kembali